Finding the right tests…
Emergency services available 24 x 7
Emergency services available 24 x 7
Finding the right tests…
Serology
An Rh antibody titre measures how concentrated anti-D antibodies are in the blood of a woman who is Rh-negative and has already been sensitized - meaning her immune system has previously made antibodies against Rh-positive blood, usually from a past pregnancy or transfusion. The lab dilutes her serum in a series of steps and reports the titre as the highest dilution at which the antibody can still be detected, written as a ratio such as 1:16. This test only applies once sensitization has already happened; it does not apply to a first pregnancy where no antibodies have yet formed, or to a woman who received Rh immune globulin before ever making her own antibodies.
The result is reported as a ratio - the last dilution of serum in which the antibody reaction is still visible. A titre of 1:16 or higher is generally treated as a critical titre for most antibodies, at which point closer fetal monitoring is recommended. A titre that climbs between two tests, even below the critical level, is watched as closely as one that starts high, since the direction of change matters as much as the number itself.
Rh sensitization happens when a Rh-negative woman's immune system is exposed to Rh-positive blood - most often her own baby's blood crossing into her circulation during pregnancy or delivery - and responds by producing anti-D antibodies. Once those antibodies exist, they stay in her system permanently and can cross the placenta in a later pregnancy if the baby is again Rh-positive. Titre testing tracks how strong that existing antibody response is.
A titre of 1:16 or above is commonly used as the threshold for referral to more detailed fetal monitoring, typically ultrasound scans that check blood flow in the fetal brain for signs of anemia. Depending on what those scans show, a pregnancy may need closer follow-up, an early delivery, or in some cases a blood transfusion for the baby before birth.
The titre test only matters because sensitization already happened. Most Rh-negative pregnant women never need it, because a preventive injection of Rh immune globulin, given during pregnancy and again after delivery, stops the antibody response before it starts. Titre monitoring is reserved for women who are already sensitized, from this pregnancy or an earlier one.
A rising titre needs a specialist's interpretation alongside gestational age and ultrasound findings - the number by itself does not predict how a specific pregnancy will go.
A titre of 1:16 or higher is generally treated as a critical level for most Rh antibodies, prompting referral for closer fetal monitoring such as Doppler ultrasound. The exact critical level can differ slightly by lab and by the specific antibody involved.
No. Most Rh-negative women never become sensitized, especially if they receive Rh immune globulin injections as recommended, so this titre test is reserved for women already known to have made anti-D antibodies.
Not by itself. A rising or critical titre prompts closer monitoring, but how the pregnancy is actually affected is judged through additional tests like fetal Doppler ultrasound, not the titre number alone.
This page is general information about the test, not medical advice. Your own report's reference ranges apply — please discuss your results with your doctor.
A rising titre usually leads to more frequent monitoring, often including ultrasound scans that check for signs of fetal anemia. Depending on the findings, your doctor may recommend earlier delivery or, in some cases, a transfusion for the baby before birth.
There is no fixed fasting requirement for this test. Ask your doctor or the centre when you book, especially if it's being drawn alongside other antenatal blood work.
Sensitization usually happens during pregnancy or delivery, so a first pregnancy typically occurs before any anti-D antibodies exist. This titre test becomes relevant only after sensitization has already occurred, which is more often seen from a second pregnancy onward if immune globulin prevention wasn't given.